CN109415347B - 酰胺取代的吡啶基三唑衍生物及其用途 - Google Patents

酰胺取代的吡啶基三唑衍生物及其用途 Download PDF

Info

Publication number
CN109415347B
CN109415347B CN201780041607.6A CN201780041607A CN109415347B CN 109415347 B CN109415347 B CN 109415347B CN 201780041607 A CN201780041607 A CN 201780041607A CN 109415347 B CN109415347 B CN 109415347B
Authority
CN
China
Prior art keywords
compounds
compound
general formula
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780041607.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109415347A (zh
Inventor
M-P.科兰-克勒佩兰
P.科尔克霍夫
T.诺伊鲍尔
C.菲尔斯特纳
E.波克
M.B.维特韦尔
K.卢斯蒂希
A.布希米勒
H.蒂内尔
K.德勒布纳
T.蒙德里茨基
H.希尔默
A.克雷奇默
C.施梅克
P.瓦斯奈雷
H.策内卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Priority to CN202110419086.1A priority Critical patent/CN113121504A/zh
Publication of CN109415347A publication Critical patent/CN109415347A/zh
Application granted granted Critical
Publication of CN109415347B publication Critical patent/CN109415347B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780041607.6A 2016-05-03 2017-05-02 酰胺取代的吡啶基三唑衍生物及其用途 Expired - Fee Related CN109415347B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110419086.1A CN113121504A (zh) 2016-05-03 2017-05-02 酰胺取代的吡啶基三唑衍生物及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16168165 2016-05-03
EP16168165.5 2016-05-03
PCT/EP2017/060356 WO2017191102A1 (en) 2016-05-03 2017-05-02 Amide-substituted pyridinyltriazole derivatives and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110419086.1A Division CN113121504A (zh) 2016-05-03 2017-05-02 酰胺取代的吡啶基三唑衍生物及其用途

Publications (2)

Publication Number Publication Date
CN109415347A CN109415347A (zh) 2019-03-01
CN109415347B true CN109415347B (zh) 2021-05-07

Family

ID=55910850

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780041607.6A Expired - Fee Related CN109415347B (zh) 2016-05-03 2017-05-02 酰胺取代的吡啶基三唑衍生物及其用途
CN202110419086.1A Pending CN113121504A (zh) 2016-05-03 2017-05-02 酰胺取代的吡啶基三唑衍生物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110419086.1A Pending CN113121504A (zh) 2016-05-03 2017-05-02 酰胺取代的吡啶基三唑衍生物及其用途

Country Status (42)

Country Link
US (4) US9988367B2 (enExample)
EP (1) EP3452463B1 (enExample)
JP (1) JP6932140B2 (enExample)
KR (1) KR20190003655A (enExample)
CN (2) CN109415347B (enExample)
AR (1) AR108262A1 (enExample)
AU (1) AU2017259870B2 (enExample)
BR (1) BR112018072542A2 (enExample)
CA (1) CA3022749A1 (enExample)
CL (1) CL2018003105A1 (enExample)
CO (1) CO2018011933A2 (enExample)
CR (1) CR20180522A (enExample)
CU (1) CU24567B1 (enExample)
CY (1) CY1124084T1 (enExample)
DK (1) DK3452463T3 (enExample)
DO (1) DOP2018000240A (enExample)
EA (1) EA035596B1 (enExample)
EC (1) ECSP18081881A (enExample)
ES (1) ES2866109T3 (enExample)
GE (1) GEP20207158B (enExample)
HR (1) HRP20210648T1 (enExample)
HU (1) HUE053908T2 (enExample)
IL (1) IL262557B (enExample)
JO (1) JOP20170105B1 (enExample)
LT (1) LT3452463T (enExample)
MA (1) MA44851B1 (enExample)
MX (1) MX381787B (enExample)
NI (1) NI201800115A (enExample)
PE (1) PE20190116A1 (enExample)
PH (1) PH12018502268A1 (enExample)
PL (1) PL3452463T3 (enExample)
PT (1) PT3452463T (enExample)
RS (1) RS61771B1 (enExample)
SG (1) SG11201809752VA (enExample)
SI (1) SI3452463T1 (enExample)
SV (1) SV2018005771A (enExample)
TN (1) TN2018000368A1 (enExample)
TW (1) TWI772295B (enExample)
UA (1) UA123791C2 (enExample)
UY (1) UY37220A (enExample)
WO (1) WO2017191102A1 (enExample)
ZA (1) ZA201808131B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
UY37222A (es) * 2016-05-03 2017-11-30 Bayer Pharma AG PROCEDIMIENTO PARA LA PREPARACIÓN DE DERIVADOS DE 1-FENILO-1,2,4-TRIAZOL SUSTITUIDOS POR 5-HIdroxIalQUILO
HRP20201746T1 (hr) 2016-05-03 2020-12-25 Bayer Pharma Aktiengesellschaft Aromatski derivati sulfonamida
US10800746B2 (en) * 2016-05-03 2020-10-13 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
US10893352B2 (en) * 2016-08-24 2021-01-12 Matthew Hawkes Programmable interactive stereo headphones with tap functionality and network connectivity
WO2018163204A1 (en) * 2017-03-08 2018-09-13 Yogee's Bioinnovations Private Limited Cathepsin-d and angiogenesis inhibitors and compositions thereof for treating breast cancer
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
US11331314B2 (en) 2017-10-24 2022-05-17 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
EP3700899A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081303A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
PE20210394A1 (es) 2017-10-24 2021-03-02 Bayer Ag Profarmacos de derivados de triazol sustituido y sus usos
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
CA3084308A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
EP3700897A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
US11020351B2 (en) * 2018-03-26 2021-06-01 Hetero Labs Limited Stable bilayer tablet compositions
US20210016350A1 (en) * 2018-04-10 2021-01-21 Hewlett-Packard Development Company, L.P. Preheat dyed build materials with preheating sources
KR20220113782A (ko) * 2019-12-24 2022-08-16 도쿄엘렉트론가부시키가이샤 성막 방법 및 성막 시스템
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
EP4626419A1 (en) * 2022-11-29 2025-10-08 The United States Government as represented by the Department of Veterans Affairs Eif4a1 inhibitors with antitumor activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854872B1 (ko) * 2003-12-22 2008-08-28 화이자 인코포레이티드 바소프레신 길항제로서의 트리아졸 유도체
CN103119028A (zh) * 2010-10-01 2013-05-22 大正制药株式会社 1,2,4-三唑酮衍生物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042466A1 (de) 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5468448A (en) 1989-12-28 1995-11-21 Ciba-Geigy Corporation Peroxide disinfection method and devices therefor
DE4107857A1 (de) 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0586513A1 (en) 1991-05-10 1994-03-16 Merck & Co. Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US6844005B2 (en) 2002-02-25 2005-01-18 Trutek Corp Electrostatically charged nasal application product with increased strength
FR2708608B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
JP3589633B2 (ja) 1997-12-17 2004-11-17 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
DE19816882A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
CA2338304A1 (en) 1998-07-24 2000-02-03 Bayer Aktiengesellschaft Substituted benzoylcyclohexandiones
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
JP3581103B2 (ja) 1999-04-01 2004-10-27 ファイザー・プロダクツ・インク ソルビトールデヒドロゲナーゼ阻害薬としてのアミノピリミジン
DE19920791A1 (de) 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19929348A1 (de) 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US6531142B1 (en) 1999-08-18 2003-03-11 The Procter & Gamble Company Stable, electrostatically sprayable topical compositions
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AR027575A1 (es) 2000-03-06 2003-04-02 Bayer Ag Benzoilciclohexenonas substituidas
US7080644B2 (en) 2000-06-28 2006-07-25 Microdose Technologies, Inc. Packaging and delivery of pharmaceuticals and drugs
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1606264B1 (en) 2003-03-14 2012-05-02 Merck Sharp & Dohme Corp. Monocyclic anilide spirohydantoin cgrp receptor antagonists
EP1689252A2 (en) 2003-06-27 2006-08-16 Berglin Corporation of Washington Machine for precision low stress coring and slicing of apples and other soft-cored or pitted fruits
WO2005097112A2 (en) 2004-03-08 2005-10-20 Wyeth Ion channel modulators
AU2005220911A1 (en) 2004-03-08 2005-09-22 Wyeth Ion channel modulators
MXPA06012510A (es) 2004-04-28 2006-12-15 Pfizer Derivados de 3-heterociclil-4-fenil-triazol como inhibidores del receptor de vasopresina via.
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006117657A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102009013642A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
CU24162B1 (es) 2010-02-27 2016-03-31 Bayer Ip Gmbh Derivados 5-aril-1,2,4-triazolona ligada a bisarilo sustituidos
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
JP6114189B2 (ja) 2010-07-09 2017-04-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および／または予防のためのその使用
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2013138860A1 (en) 2012-03-22 2013-09-26 Biota Europe Limited Antibacterial compounds
SG11201703199UA (en) 2014-11-03 2017-05-30 Bayer Pharma AG Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
UY37222A (es) * 2016-05-03 2017-11-30 Bayer Pharma AG PROCEDIMIENTO PARA LA PREPARACIÓN DE DERIVADOS DE 1-FENILO-1,2,4-TRIAZOL SUSTITUIDOS POR 5-HIdroxIalQUILO
US10800746B2 (en) * 2016-05-03 2020-10-13 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854872B1 (ko) * 2003-12-22 2008-08-28 화이자 인코포레이티드 바소프레신 길항제로서의 트리아졸 유도체
CN103119028A (zh) * 2010-10-01 2013-05-22 大正制药株式会社 1,2,4-三唑酮衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《Preparation of triazolobenzodiazepine derivatives as Vasopressin V1a antagonists》;David M. Beal等;《Tetrahedron Letters》;20110822;第52卷(第45期);5913-5917 *

Also Published As

Publication number Publication date
JP6932140B2 (ja) 2021-09-08
ES2866109T3 (es) 2021-10-19
CN113121504A (zh) 2021-07-16
MX381787B (es) 2025-03-13
SG11201809752VA (en) 2018-12-28
RS61771B1 (sr) 2021-05-31
US20180251447A1 (en) 2018-09-06
UY37220A (es) 2017-11-30
JP2019514945A (ja) 2019-06-06
AU2017259870B2 (en) 2021-07-15
MX2018013335A (es) 2019-05-09
DOP2018000240A (es) 2019-03-15
WO2017191102A1 (en) 2017-11-09
BR112018072542A2 (pt) 2019-03-26
LT3452463T (lt) 2021-04-26
AR108262A1 (es) 2018-08-01
US20190144423A1 (en) 2019-05-16
EP3452463B1 (en) 2021-03-24
PE20190116A1 (es) 2019-01-16
CL2018003105A1 (es) 2019-02-15
NI201800115A (es) 2019-03-14
CU24567B1 (es) 2022-01-13
TN2018000368A1 (en) 2020-06-15
SI3452463T1 (sl) 2021-07-30
CN109415347A (zh) 2019-03-01
CO2018011933A2 (es) 2018-11-22
US20170320854A1 (en) 2017-11-09
IL262557B (en) 2022-01-01
PH12018502268A1 (en) 2019-07-15
KR20190003655A (ko) 2019-01-09
CR20180522A (es) 2019-01-15
ZA201808131B (en) 2021-05-26
EP3452463A1 (en) 2019-03-13
MA44851B1 (fr) 2021-09-30
DK3452463T3 (da) 2021-04-26
EA035596B1 (ru) 2020-07-14
CY1124084T1 (el) 2022-05-27
TWI772295B (zh) 2022-08-01
CA3022749A1 (en) 2017-11-09
US11091463B2 (en) 2021-08-17
TW201806941A (zh) 2018-03-01
US20200017473A1 (en) 2020-01-16
ECSP18081881A (es) 2018-11-30
HUE053908T2 (hu) 2021-07-28
US9988367B2 (en) 2018-06-05
HRP20210648T1 (hr) 2021-05-28
AU2017259870A1 (en) 2018-11-15
JOP20170105B1 (ar) 2022-03-14
PL3452463T3 (pl) 2021-08-09
GEP20207158B (en) 2020-10-12
US10472348B2 (en) 2019-11-12
CU20180134A7 (es) 2019-06-04
EA201892505A1 (ru) 2019-04-30
IL262557A (en) 2018-12-31
MA44851A (fr) 2019-03-13
SV2018005771A (es) 2019-01-04
PT3452463T (pt) 2021-04-28
UA123791C2 (uk) 2021-06-02

Similar Documents

Publication Publication Date Title
CN109415347B (zh) 酰胺取代的吡啶基三唑衍生物及其用途
US10815205B2 (en) Amide-substituted phenyltriazole derivatives and uses thereof
US10525041B2 (en) Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
US10526314B2 (en) Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
US20190119251A1 (en) Amide-substituted aryltriazole derivatives and uses thereof
US11298367B2 (en) Prodrugs of substituted triazole derivatives and uses thereof
US11230540B2 (en) Substituted triazole derivatives and uses thereof
WO2019081291A1 (en) PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
HK40055794A (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
HK40005398A (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
HK40005398B (zh) 酰胺取代的吡啶基三唑衍生物及其用途
HK40021282A (en) Prodrugs of substituted triazole derivatives and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40005398

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210507

CF01 Termination of patent right due to non-payment of annual fee